Lečenje gojaznosti iz perspective kliničara

Lečenje gojaznosti

  • Snežana Polovina Univerzitetski klinički centar Srbije, Klinika za endokrinologiju, dijabetes i bolesti metabolizma
  • Mirjana Šumarac-Dumanović Univerzistetski klinički centar Srbije, Klinika za endokrinologiju, dijabetes i bolesti metabolizma
  • Dragan Micić Srpska akademija nauka i umetnosti, Odeljenje medicinskih nauka
DOI: https://doi.org/10.5937/arhfarm74-50566
Ključne reči: gojaznost, dijetoterapija, vežbanje, lekovi za lečenje gojaznosti, barijatrijska hirurgija, inflamacija niskog stepena

Sažetak


Globalna epidemija gojaznosti zahvatila je skoro svaku zemlju na svetu, izazivajući ogromno opterećenje socijalnog i zdravstvenog sistema. Iako su u mnogim zemljama uvedene brojne mere za obuzdavanje epidemije, gojaznost je i dalje u porastu. Važan korak u ovoj oblasti napravljen je kada je gojaznost prihvaćena kao bolest. Prepoznavanje gojaznosti kao bolesti omogućava vladama i državama da razviju sopstvene planove za mera za kontrolu epidemije gojaznosti. Gojaznost je prepoznata kao problem od davnina i predlagane su različite mere. Savremeni tretman gojaznosti se trenutno zasniva na sledećim terapijskim principima: dijeta, vežbanje, psihološka podrška, farmakološko lečenje i barijatrijska hirurgija. Istorija farmakološkog lečenja je prilično duga i puna povlačenja lekova zbog raznih razloga. Nove perspektive i obećavajući rezultati stigli su sa klasom lekova na bazi inkretina. Ovi lekovi su razvijeni kao agonisti gastrointestinalnih peptida u monopeptidnom obliku ili kao kombinacija dva ili tri različita agonista, postižući rezultate slične onima koje postiže barijatrijska hirurgija. Trenutno je u procesu razvoja oko 70 različitih terapijskih principa. Problemi na tržištu lekova za lečenje gojaznosti su njihove visoke cene, ograničen kapacitet za proizvodnju i nedostatak iskustva po pitanju efekata nakon dugotrajne primene.

Biografija autora

Snežana Polovina, Univerzitetski klinički centar Srbije, Klinika za endokrinologiju, dijabetes i bolesti metabolizma

Center for Obesity

Reference

Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.

Duncan I, Kerr D, Aggarwal R, Huynh N, et alet al. New drugs for obesity, is the excitement affordable? Population Health Manag 2023;26(5):356-357.

Gargantilla Madera P, Arroyo Pardo N. Hasday: tratamiento de la obesidad en el siglo x. Endocrinol Nutr. 2016;63:100-101.

Bray GA, Heisel WE, Afshin A, Jensen MD, Dietz WH, Long M, et al. The Science of Obesity Management: An Endocrine Society Scientific Statement. Endocr Rev. 2018;39(2):79-132.

Quarta C, Claret M, Zeltser LM, Williams KW, Yeo GSH, Tschöp MH, . POMC neuronal heterogeneity in energy balance and beyond: an integrated view. Nat Metab. 2021 Mar;3(3):299-308.

Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Reviews Drug Discov. 2022;21(3):201-223.

Gutt S, Schraier S, Gonz S, GBagnes MF, Yu M, González CD, Di Girolamo G. Long-term pharmacotherapy of obesity in patients that have undergone bariatric surgery: pharmacological prevention and management of body weight regain. Expert Opin Pharmacother. 2019;20(8):939-947.

Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr. 2005;82(1 Suppl):222S-225S.

Gupta H. Barriers to and Facilitators of Long Term Weight Loss Maintenance in Adult UK People: A Thematic Analysis. Int J Prev Med. 2014;5(12):1512-20.

Melby CL, Paris HL, Foright RM, Peth J. Attenuating the Biologic Drive for Weight Regain Following Weight Loss: Must What Goes Down Always Go Back Up? Nutrients. 2017;9(5):468.

Grzelka K, Wilhelms H, Dodt S, Dreisow ML, Madara JC, Walker SJ, et al. A synaptic amplifier of hunger for regaining body weight in the hypothalamus. Cell Metab. 2023;35(5):770-785.e5.

Furigo IC, Teixeira PDS, de Souza GO, Couto GCL, Romero GG, Perelló M, et al. Growth hormone regulates neuroendocrine responses to weight loss via AgRP neurons. Nat Commun. 2019;10(1):662.

van Baak MA, Mariman ECM. Mechanisms of weight regain after weight loss - the role of adipose tissue. Nat Rev Endocrinol. 2019;15(5):274-287.

van Baak, MA, Mariman, ECM. Obesity-induced and weight-loss-induced physiological factors affecting weight regain. Nat Rev Endocrinol. 2023;19(11):655–670.

Garvey T. Is obesity or adiposity-based chronic disease curable: the set point theory, the environment, and second-generation medications. Endocr Pract. 2022;28(2):214-222.

Yurista S, Eder R, Feeley M, Kodur N, Tang WHW, Nguyen CT. A Closer Look at ACC/AHA and ESC Guidelines for Managing Obesity and Overweight in Adults. JACC Adv. 2023;2(7):100570.

Bloch MJ. The dietary approaches to stop hypertension (DASH) diet-promise unmet. J Am Soc Hypert. 2017;11(6):323–324.

Richardson LA, Izuora K, Basu A. Mediterranean diet and its association with cardiovascular disease risk factors: A scoping review. Int. J Environ Res Public Health. 2022;19(19):12762.

Tettamanzi F, Bagnardi V, Louca P, Nogal A, Monti GS, Mambrini SP, et al. A high protein diet is more effective in improving insulin resistance and glycemic variability compared to a mediterranean diet—a cross-over controlled in patient dietary study. Nutrients. 2021;13(12):4380.

Chao A, Quigley KM, Wadden T. Dietary interventions for obesity: clinical and mechanistic findings. J Clin Invest. 2021;131(1):e140065.

Wiechert M, Holzapfel C. Nutrition Concepts for the Treatment of Obesity in Adults. Nutrients. 2022;14(1):169.

Oppert JM, Bellicha A, van Baak M, Battista F, Beaulieu K, Blundell JE, et al. Exercise training in the management of overweight and obesity in adults: Synthesis of the evidence and recommendations from the European Association for the Study of Obesity Physical Activity Working Group. Obes Rev. 2021;22(S4):e13273.

Gjermeni, E, Kirstein AS, Kolbig F, Kirchhof M, Bundalian L, Katzmann JL, et al. Obesity-An Update on the Basic Pathophysiology and Review of Recent Therapeutic Advances. Biomolecules. 2021;11(10):1426.

Brandfon S, Eylon A, Khanna D, Parmar MS. Advances in Anti-obesity Pharmacotherapy: Current Treatments, Emerging Therapies, and Challenges. Cureus. 2023;15(10):e46623.

Chakhtoura M, Haber R, Ghezzawi, Rhayem C, Tcheroyan R, Mantzorosc C. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. eClinicalMedicine. 2023;58:101882.

Kosmalski M, Deska K, BK, B, RB, R K, BK, Besk M, Pietras T. Pharmacological Support for the Treatment of Obesity-Present and Future. Healthcare (Basel). 2023 Feb 2;11(3):433.

Onakpoya IJ, Lee JJ, Mahtani KR, Aronson JK, Heneghan CJ. Naltrexone-bupropion (Mysimba) in management of obesity: A systematic review and meta-analysis of unpublished clinical study reports. Br J Clin Pharmacol. 2020;86(4):646-667.

Thomas B, Lindblad AJ, Luu T, Paige A. Naltrexone-bupropion for weight loss. Can Fam Physician. 2023;69(9):627.

Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022 Mar;57:101351.

Le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, et al. SCALE Obesity Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399-1409.

Lundgren JR, Janus C, Jensen SBK, Juhl CR, Olsen LM, Christensen RM, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021;384(18):1719-1730.

Mozaffarian D. GLP-1 Agonists for Obesity—A New Recipe for Success? JAMA. 2024 Mar 26;331(12):1007-1008.

Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity? Int J Obes (Lond). 2024 Feb 1. doi: 10.1038/s41366-024-01473-y. Epub ahead of print.

Naeem M, Imran L, Banatwala UESS. Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence. Health Sci Rep. 2024 Feb 5;7(2):e1864.

Roomy MA, Hussain K, Behbehani HM, Abu-Farha J, Al-Harris R, Ambi AM, et al. Therapeutic advances in obesity management: an overview of the therapeutic interventions. Front Endocrinol (Lausanne). 2024 Apr 23;15:1364503.

Busetto L, Bettini S, Makaronidis J, Roberts CA, Halford JCG, Batterham RL. Mechanisms of weight regain. Eur J Intern Med. 2021;93:3-7.

Lucas E, Simmons O, Tchang B, Aronne L. Pharmacologic management of weight regain following bariatric surgery. Front Endocrinol. 2023;13:1043595.

Objavljeno
2024/06/28
Broj časopisa
Vol. 74 Br. Notebook 3 (2024): Arhiv za farmaciju
Rubrika
Pregledni (Revijalni) rad
Autori koji objavljuju u ovom časopisu pristaju na sledeće uslove:

  1. Autori zadržavaju autorska prava i pružaju časopisu pravo prvog objavljivanja rada i licenciraju ga "Creative Commons Attribution licencom" koja omogućava drugima da dele rad, uz uslov navođenja autorstva i izvornog objavljivanja u ovom časopisu.

  2. Autori mogu izraditi zasebne, ugovorne aranžmane za neekskluzivnu distribuciju članka objavljenog u časopisu (npr. postavljanje u institucionalni repozitorijum ili objavljivanje u knjizi), uz navođenje da je članak izvorno objavljen u ovom časopisu.

  3. Autorima je dozvoljeno i podstiču se da postave objavljeni članak onlajn (npr. u institucionalni repozitorijum ili na svoju internet stranicu) pre ili tokom postupka prijave rukopisa, s obzirom da takav postupak može voditi produktivnoj razmeni ideja i ranijoj i većoj citiranosti objavljenog članka (Vidi Efekti otvorenog pristupa).